Homburger: ADC on the Underwritten Offering by a Selling Shareholder

ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a price of USD 5.00 per share. ADCT itself did not sell any shares in the offering. The Swiss company is helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates.

The offering included participation from Redmile Group, Perceptive Advisors, Frazier Life Sciences and Surveyor Capital (a Citadel company) along with other institutional investors.

The Homburger team was led by partner Daniel Häusermann (pictured left) and included associate Estelle Piccard (pictured right), both corporate / m&a, capital markets.

mercedes.galan

SHARE